Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TheraQuest Biosciences, a development stage pain management company, has announced that the FDA has accepted its investigational new drug application for TQ-1015, its abuse deterrent extended release strong opioid.
Subscribe to our email newsletter
TQ-1015 is being developed using Securel, TheraQuest’s abuse deterrent technology. TQ-1015 is a once-a-day extended release opioid analgesic for the treatment of chronic pain.
Najib Babul, CEO of TheraQuest, said: “Sustained release opioids are the standard of care for the management of chronic pain. Unfortunately, it is easy to defeat the sustained release mechanism of such dosage forms, making them subject to drug diversion and drug abuse. The TQ-1015 dosage form is highly tamper resistant, when compared to OxyContin, thereby minimizing abuse by recreational drug users and drug addicts.”